Michael Handley

Mr. Michael K.
Handley is a Chairman, President & Chief Executive Officer at Sparta Healthcare Acquisition Corp.
and a Chief Executive Officer at Aletheia Therapeutics, Inc. He is on the Board of Directors at PetVivo Holdings, Inc., Valion Bio, Inc., Aletheia Therapeutics Corp., Makamer Holdings, Inc., Makamer, Inc. and Reven Holdings, Inc. Mr. Handley was previously employed as a President, Chief Executive Officer & Director by Cleveland BioLabs, Inc., a Chairman, President & Chief Executive Officer by Statera Biopharma, Inc., a President, Chief Executive Officer & Director by Cytocom, Inc. /Old/, a President, Chief Executive Officer & Director by Immune Therapeutics, Inc., a Chief Executive Officer & Director by Marizyme, Inc., a Chairman by Medavate Corp., a Chief Executive Officer & Director by Armis Biopharma, Inc., a Vice President-Regulatory, Clinical & Quality by Vessix Vascular, Inc., a Global Head-Regulatory by Acclarent, Inc., a Chief Compliance Officer & VP-Regulatory by The Spectranetics Corp., a CEO, VP-Regulatory, Business Development & Quality by AccelaPure Corp., and a Senior Principal by PRTM Management Consultants LLC.
He also served on the board at Coeptis Therapeutics, Inc. He received his undergraduate degree from Colorado State University and an MBA from Pepperdine Graziadio Business School.